Markets:

Overview

News

Currencies

International

Treasuries

AbbVie (NY:ABBV)

250.94 -6.47 (-2.51%)

Official Closing Price Updated: 6:30 PM EDT, Jul 31, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about AbbVie

< Previous 1 2 3 4 5 6 7 8 9

...

92 93 Next >

Here's How Much $1000 Invested In AbbVie 5 Years Ago Would Be Worth Today ↗

Today 16:00 EDT

AbbVie (NYSE:ABBV) has outperformed the market over the past 5 years by 5.65% on an annualized basis producing an average annual return of 16.8%. Currently, AbbVie has a market capitalization of...

Via Benzinga

AbbVie Q2 Earnings Call Highlights ↗

Today 11:04 EDT

AbbVie (NYSE:ABBV) reported second-quarter 2026 results that exceeded its expectations, supported by double-digit growth in its immunology and neuroscience businesses, and raised its full-year revenue...

Via MarketBeat

Topics ETFs Earnings

AbbVie Stock Falls as Guidance Cut Overshadows Strong Q2 Earnings Beat ↗

Today 10:16 EDT

AbbVie Inc. (NYSE: ABBV) shares are retreating Friday after trimming full-year adjusted EPS guidance below analyst targets.

Via Benzinga

AbbVie’s (NYSE:ABBV) Q2 CY2026: Beats On Revenue

Today 8:59 EDT

Pharmaceutical company AbbVie (NYSE:ABBV) beat Wall Street’s revenue expectations in Q2 CY2026, with sales up 10.2% year on year to $16.99 billion. Its non-G...

Via StockStory

Get insights into the top movers in the S&P500 index of Friday's pre-market session. ↗

Today 8:35 EDT

Via Chartmill

AbbVie (NYSE:ABBV) Shares Slip on Apogee Acquisition Despite In-Line Q2 Results ↗

Today 8:20 EDT

Via Chartmill

Cannabis Theme's Hidden Strength: Established Players Outshining Pure Plays ↗

July 30, 2026

Via Chartmill

Topics Cannabis

What To Expect From AbbVie’s (ABBV) Q2 Earnings

July 29, 2026

Pharmaceutical company AbbVie (NYSE:ABBV) will be announcing earnings results this Friday before market hours. Here’s what to look for. AbbVie beat analysts’...

Via StockStory

Topics Artificial Intelligence

Meet the Stock That's Obliterating Eli Lilly, Johnson & Johnson, and AbbVie Right Now ↗

July 29, 2026

But is that performance sustainable?

Via The Motley Fool

AbbVie Has Raised Its Dividend for 53 Straight Years and Still Looks Attractively Valued. Is This Dividend King the Smartest Buy in Healthcare Right Now? ↗

July 29, 2026

AbbVie still looks like a compelling buy at its all-time high.

Via The Motley Fool

Topics Intellectual Property

Should You Buy AbbVie Stock Hand Over Fist Before July 31? ↗

July 27, 2026

The recent rally could pave the way for "sell the news" volatility, but don't let this scare you out of a long-term position.

Via The Motley Fool

Topics Earnings Intellectual Property

Better Dividend King to Buy Right Now: AbbVie or Johnson & Johnson? ↗

July 26, 2026

Both have very promising futures.

Via The Motley Fool

Why Wall Street Can't Get Enough of This Dividend King ↗

July 25, 2026

AbbVie has an attractive 2.7% yield, a solid pharmaceutical business, and is clearly focused on its dividend.

Via The Motley Fool

Topics Intellectual Property

2 Top Growth Stocks to Buy Right Now Without Any Hesitation ↗

July 24, 2026

There are plenty of reasons to love these companies.

Via The Motley Fool

I'd Double a Position in These 3 Dividend Stocks Right Now Without Any Hesitation ↗

July 23, 2026

When quality goes on sale, it's time to back up the truck.

Via The Motley Fool

Topics Intellectual Property

3 Reasons to Buy AbbVie Stock Like There's No Tomorrow ↗

July 21, 2026

It looks like a great buy-and-hold option.

Via The Motley Fool

Topics Intellectual Property

PJP vs. IYH: Which Healthcare ETF Is the Better Buy? ↗

July 20, 2026

PJP delivered a higher return over the past year -- but IYH charges lower fees and pays a higher dividend yield.

Via The Motley Fool

Topics ETFs

How Will AbbVie's $10.9 Billion Acquisition of Apogee Impact Its Dividend? ↗

July 19, 2026

There's no need to panic.

Via The Motley Fool

My 2 Favorite Dividend Kings to Buy Right Now ↗

July 19, 2026

They can help stabilize your portfolio in these otherwise volatile times.

Via The Motley Fool

Topics Intellectual Property

Here's How Much $1000 Invested In AbbVie 10 Years Ago Would Be Worth Today ↗

July 17, 2026

AbbVie (NYSE:ABBV) has outperformed the market over the past 10 years by 1.69% on an annualized basis producing an average annual return of 14.83%. Currently, AbbVie has a market capitalization of...

Via Benzinga

3 Rock-Solid Dividend Stocks to Buy and Hold for Decades ↗

July 14, 2026

AbbVie, Enbridge, and Coca-Cola pay high dividends and are the types of stocks that investors can buy and forget about.

Via The Motley Fool

Topics Intellectual Property

Donald Trump's Drug-Pricing Deals Are Reshaping Big Pharma -- Here's What That Means for Pfizer, AbbVie, and Bristol Myers Squibb ↗

July 14, 2026

Drug pricing matters, but pipelines matter even more.

Via The Motley Fool

Topics Government Intellectual Property

3 Dividend Stocks Built for Long-Term Buy-and-Hold Investors ↗

July 13, 2026

You need to look beyond the tech sector to find great dividend stocks for the long term.

Via The Motley Fool

Topics Artificial Intelligence

AbbVie Is Already a Dividend King. Here's Why the $10.9 Billion Apogee Deal Could Make It a Dynasty ↗

July 11, 2026

AbbVie inherited its status as a Dividend King, but it is building a strong foundation to continue the dividend streak.

Via The Motley Fool

Topics Intellectual Property

5 Dividend Kings to Buy in July with Irristable Value and Yield ↗

July 08, 2026

Five Dividend Kings—Procter & Gamble, Hormel, Stanley Black & Decker, Genuine Parts and Lowe's—trade at discounted valuations, offering attractive yields despite near-term business headwinds.

Via MarketBeat

3 Reasons to Buy Novo Nordisk Stock ↗

July 07, 2026

The stock is down, but it isn't out yet.

Via The Motley Fool

U.S. Healthcare Spending Just Hit $5.7 Trillion and Continues to Grow: 2 Stocks to Buy to Profit From the Trend ↗

July 07, 2026

Good medical care will always be in high demand, which makes some healthcare stocks strong long-term picks.

Via The Motley Fool

Abivax: Wall Street Catches Up to the Data ↗

July 07, 2026

Abivax stock surged over 40% after positive Phase 3 data on ulcerative colitis drug Obefazimod and a $920 million share offering that underwriters fully exercised, signaling strong institutional...

Via MarketBeat

3 High-Yield Dividend Stocks to Buy and Hold Forever (Hint: AbbVie Makes the List) ↗

July 07, 2026

It doesn't get much more dependable and lucrative than the healthcare industry.

Via The Motley Fool

Topics Intellectual Property

The Dividend ETF Quietly Outperforming the S&P 500 ↗

July 07, 2026

This dividend ETF's focus beyond yield continues to pay off for investors.

Via The Motley Fool

Topics ETFs Stocks

< Previous 1 2 3 4 5 6 7 8 9

...

92 93 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.